Guo Jiubiao, Zhang Ximeng, Chen Xinchun, Cai Yi
College of Pharmacy, Shenzhen Technology University, Shenzhen, China.
Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pathogen Biology, School of Medicine, Shenzhen University, Shenzhen, China.
Front Microbiol. 2022 Apr 26;13:845229. doi: 10.3389/fmicb.2022.845229. eCollection 2022.
Tuberculosis (TB) continues to threaten many peoples' health worldwide, regardless of their country of residence or age. The current diagnosis of TB still uses mainly traditional, time-consuming, and/or culture-based techniques. Efforts have focused on discovering new biomarkers with higher efficiency and accuracy for TB diagnosis. Proteomics-the systematic study of protein diversity-is being applied to the discovery of novel protein biomarkers for different types of diseases. Mass spectrometry (MS) technology plays a revolutionary role in proteomics, and its applicability benefits from the development of other technologies, such as matrix-based and immune-based methods. MS and derivative strategies continuously contribute to disease-related discoveries, and some promising proteomic biomarkers for efficient TB diagnosis have been identified, but challenges still exist. For example, there are discrepancies in the biomarkers identified among different reports and the diagnostic accuracy of clinically applied proteomic biomarkers. The present review summarizes the current status and future perspectives of proteomics in the field of TB biomarker discovery and aims to elicit more promising findings for rapid and accurate TB diagnosis.
结核病（TB）仍然在全球范围内威胁着许多人的健康，无论他们居住在哪个国家或年龄多大。目前结核病的诊断仍主要使用传统的、耗时的和/或基于培养的技术。人们致力于发现效率更高、准确性更高的新型生物标志物用于结核病诊断。蛋白质组学——对蛋白质多样性的系统研究——正被应用于发现不同类型疾病的新型蛋白质生物标志物。质谱（MS）技术在蛋白质组学中发挥着革命性作用，其适用性得益于其他技术的发展，如基于基质和基于免疫的方法。质谱及其衍生策略不断为与疾病相关的发现做出贡献，并且已经鉴定出一些用于高效结核病诊断的有前景的蛋白质组学生物标志物，但挑战依然存在。例如，不同报告中鉴定出的生物标志物存在差异，以及临床应用的蛋白质组学生物标志物的诊断准确性问题。本综述总结了蛋白质组学在结核病生物标志物发现领域的现状和未来前景，旨在引出更多用于快速准确结核病诊断的有前景的发现。
